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Conclusions: These results suggest that an exercise (MIA and 
PRE) prescription for patients on HAART boosts their CD4 count. 
Importantly, CD4 count may be boosted more by MIA than by PRE 
exercises in patients on HAART and HAART-naive, respectively. The 
change factor suggests supports this conclusion and the effect size 
are of clinical significance.
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Background: Aldose reductase (AR) plays a pivotal role in the polyol 
pathway. In the diabetic condition, it is found to cause accumulation 
of polyol in lens fibers, causing influx of water and generation of 
osmotic stress leading to sugar cataracts. The objective of this study 
was to evaluate the AR inhibitory activity and anticataract activity of 
methanolic extract of Punica granatum Linn. fruit (MPGF).
Methods: AR inhibitory activity was evaluated in vitro in goat lenses. 
For the cataract model, goat lenses were incubated in artificial aque-
ous humor containing 55 mM of glucose with MPGF in different 
concentrations at room temperature for 72 hours. Opacification of 
the lens was assessed by counting the number of squares when placed 
over a graph paper, and biochemical parameters were estimated.
Results: MPGF exhibited in vitro AR inhibition activity with an 
IC50 of 300.43 (4.36) µg/mL. Glucose-induced opacification of the 
goat lens began 24 hours after incubation and was completed in 72 
hours. Cataractous lenses showed higher malondialdehyde and lower 
reduced glutathione, superoxide dismutase, and total proteins. Lenses 
treated with MPGF prevented formation and progress of cataract by 
glucose, as evidenced by biochemical parameters.
Conclusions: MPGF prevented cataract formation due to inhibition 
of the AR enzyme.
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Background: Hypertension is a serious global public health problem. 
It accounts for 10% of all deaths in India and is the leading noncom-
municable disease.1 Recent studies have shown that the prevalence 
of hypertension is 25% in urban and 10% in rural people in India.2 
It exerts a substantial public health burden on cardiovascular health 
status and health care systems in India.3 Antihypertensive treatment 
effectively reduces hypertension-related morbidity and mortality.1 
The cost of medications has always been a barrier to effective treat-
ment. The increasing prevalence of hypertension requires use of cost-
effective treatment for the effective management of the disease.
Objectives: The present study assesses the cost-effectiveness of anti-
hypertensive drugs in patients with hypertension from Mumbai, 
India.
Methods: A prospective cross-sectional study was conducted to 
assess the cost-effectiveness of antihypertensive drugs. Face-to-face 
interviews were conducted by using a validated questionnaire in a 
total of 136 (66 males, 70 females) patients with hypertension from 
F-North Ward, Mumbai, India. Cost-effectiveness was determined 
on the basis of a drug’s cost, efficacy, adverse drug reactions, safety 
of administration, frequency of administration, and bioavailability.
Results: Atenolol was most cost-effective (international normalized 
ratio [INR]: 5.5/unit of effectiveness), followed by the amlodipine 
+ losartan combination (INR: 5.6/unit of effectiveness) and amlodi-
pine (INR: 6.3/unit of effectiveness) in the present study. Thirty-eight 
(28%) patients received combination therapy. Lisinopril prescribed 
to16 (11.8%) patients was the least cost-effective drug (INR: 17.2/unit 
of effectiveness).
Conclusions: Prescriptions of cost-effective antihypertensive drugs 
(73.5%) were more common than less cost-effective antihypertensive 
drugs (26.5%) in hypertensive patients from Mumbai, India. Most 
of the patients (72%) were prescribed monotherapy in the treatment 
of hypertension.
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Background: Diabetes is fast gaining the status of a potential epi-
demic in India, with > 62 million individuals currently diagnosed 
with the disease.1 India currently faces an uncertain future in rela-
tion to the potential burden that diabetes may impose on the coun-
try. An estimated US$ 2.2 billion would be needed to sufficiently 
treat all cases of type 2 diabetes mellitus (T2DM) in India.2 Many 
interventions can reduce the burden of this disease. However, health 
care resources are limited; thus, interventions for diabetes treatment 
should be prioritized.
Objectives: The present study assesses the cost-effectiveness of anti-
diabetic drugs in patients with T2DM from Mumbai, India.
Methods: A prospective cross-sectional study was performed to 
assess the cost-effectiveness of antidiabetic drugs in patients with 
T2DM. Face-to-face interviews were conducted by using a validated 
questionnaire in a total of 152 (76 males, 76 females) patients with 
T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was 
determined on the basis of a drug’s cost, efficacy, adverse drug reac-
tions, safety of administration, frequency of administration, and 
bioavailability.
Results: The glimepiride plus pioglitazone combination was the 
most cost-effective (international normalized ratio [INR]: 3.7/unit 
of effectiveness), followed by glimepiride (INR: 6.6/unit of effective-
ness) prescribed in nonobese patients with T2DM. Glimepiride plus 
metformin was the most cost-effective (INR: 5.9/unit of effectiveness) 
followed by metformin (INR: 6.7/unit of effectiveness) prescribed in 
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obese patients with T2DM. Cost-effectiveness (INR/unit of effective-
ness) varied from 3.7 to 45.2. Seventeen percent of the patients with 
T2DM included in this study received less cost-effective antidiabetic 
drugs.
Conclusions: Prescriptions of cost-effective antidiabetic drugs (83%) 
were more common than less cost-effective antidiabetic drugs (17%) 
in patients with T2DM from Mumbai, India.
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Background: Immunization is the most cost-effective intervention 
for infectious diseases, which are the major cause of morbidity and 
mortality worldwide. Vaccines not only protect the individual who 
is vaccinated but also reduce the burden of infectious vaccine-pre-
ventable diseases for the entire community.1 Adult vaccination is very 
important given that > 25% of mortality is due to infectious diseases.2 
There is a scarcity of information on the vaccination status of young 
adults and the role of socioeconomic conditions in India.
Objectives: The present study explored the adult vaccination status 
and influence of income and education of parents on adult vaccina-
tion status in university students from Mumbai, India.
Methods: This descriptive study was performed from January to 
April 2015 among undergraduate pharmacy students from Mumbai 
University, India, by using a validated study questionnaire. Students 
were contacted by a study team member in their classrooms and were 
given a brief introduction about the research project. Those who 
desired to participate in the study were explained the purpose and 
objectives of the study. On the basis of the eligibility criteria (those 
who gave written informed consent and were between the age group 
of 18–25 years), 149 students were selected for the present study. 
A total of 8 vaccines (namely, Tdap/DTP, varicella, measles-mumps-
rubella [MMR], influenza, pneumococcal, hepatitis A, hepatitis B, 
and meningococcal) were included in this study for all the respond-
ents. In addition to these vaccines, human papillomavirus (HPV) 
vaccine was also included for female respondents.
Results: There were total of 149 (75 males and 74 females) respond-
ents with a mean age of 21.5 years. The top 3 immunizations were 
Td/Tdap (97.3%), MMR (66.4%), and hepatitis B (55%) among the 
respondents. Only 4 (5.5%) female respondents had been immunized 
against HPV. The lowest income group (< 50,000 INR/month) had 
the least vaccination coverage for all the vaccines, except for MMR 
and HPV. Vaccination coverage was lesser for respondents with par-
ent’s education below a high school than those with parent’s edu-
cation of graduation and above, except for pneumococcal vaccine.
Conclusions: India’s National Centre for Disease Control has recom-
mended Td/Tdap, MMR, and varicella for all adults and influenza, 
pneumococci, hepatitis A, hepatitis B, meningococcal, and HPV for 
adults with certain risk factors. Td/Tdap (97.3%) and MMR (66.4%) 
coverage was in line with the recommendations. For all the other 
vaccines, the coverage was low, varying from 5.5% to 35.4%. The 
vaccination coverage was better in respondents with higher educated 
and higher income parents. We suggest that patient education, plan-
ning by government for the implementation of a policy for adult 
vaccination, and involvement of physicians are needed for better 
adult vaccination coverage.
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versity students.
Disclosure of Interest: None declared.
References
1. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces 
disease, disability, death and inequity worldwide. Bull World 
Health Organ 2008; 86:140–146.
2. Verma R, Khanna P, Chawla S. Adult immunization in India: 
Importance and recommendations. Human Vaccines & Immuno­
therapeutics. 2015; 11(9):2180–2182.
In defenSe of MedIcAlly enhAncIng huMAn 
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Our species may plausibly boast that, in the relatively short period 
since it first emerged, it has enormously advanced in knowledge, 
science, and technical progress. When it comes to our moral develop-
ment, however, the distance we have covered is comparatively negligi-
ble. As a result, man today resembles a mighty giant who has no clue 
how to use his powers; and just like a child playing with grenades, 
man has become utterly dangerous to himself, to other species, and 
to the globe in general. The situation is bound to steadily deteriorate 
as long as the gap between our powers and our morality continues 
to increase. What if, however, we could medically accelerate our 
moral development? Even better, what if we could one and for all 
render our species totally immune to certain vices? The advances in 
biomedicine nowadays seem to hold such a promise. In this essay, 
I will discuss the prospect of medically intervening with the moral 
disposition of humans in such a way as to even eliminate morally 
unjustifiable choices. I will claim that such an intervention would 
not necessarily compromise either the free will or the autonomy of 
moral agents. To support my view, I will provide a set of arguments 
based on the Kantian tradition in ethics, since the opponents of moral 
enhancement mostly evoke arguments that focus on autonomy and 
free will. I will conclude with the view that moral enhancement by 
means of pharmaceutical intervention might even be a perfect duty 
for moral agents in the light of Kantian ethics.
Key words: autonomy, biomedicine, free will, Kantian ethics, moral 
enhancement, utilitarianism.
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Background: Many clinical trials, including those performed in the 
developing world, are designed and conducted by academics without 
pharmaceutical sponsorship, input, or supervision. Although many 
academics are adept at asking and answering basic scientific ques-
tions, unfortunately few academic institutions or investigators are 
equipped to provide the same quality of clinical trial design, conduct, 
and oversight as those done by the pharmaceutical industry.
